3. Patient registry development One of the key TREAT-NMD infrastructures built up in the last 2 years is a global patient registry for DMD and SMA comprising more than 20 national patient registries worldwide. The DMD registries now hold more than 9,000 individual patient entries

with standardized items and consent facilitating and accelerating clinical research and clinical Inhibitors,research,lifescience,medical trials while giving patients improved access to relevant information on standards of diagnosis and care. Most innovative therapies for patients suffering from rare NMDs are expected to act on gene-specific molecular pathways. In some areas, the specific mutation will determine the applicability

of a particular therapeutic Inhibitors,research,lifescience,medical technique. Therefore, patient registries for NMDs need to be DZNeP supplier gene-based and annotating each patient’s mutation correctly is of high importance. Clinical information Inhibitors,research,lifescience,medical needs to be captured in a standardized way and updated regularly. For ease of use, and to respond to the need for regular updating, a core set of mandatory data are generated for each disorder. Participation of disease experts is essential for curation of genetic and clinical information and adherence to the TREAT-NMD charter provides assurance of best practice in regulatory and ethical domains. Access to the data in the global registry is regulated by an international oversight committee. TREAT-NMD is now working with other Inhibitors,research,lifescience,medical groups to support similar developments for other rare Inhibitors,research,lifescience,medical NMDs such as the Congenital Muscular Dystrophies (with Cure CMD) and Myotonic Dystrophy (with the Marigold Foundation), and others representing several genetic entities. For some of these disorders, leading scientists have set up local registries or private databases

that may not be generally available to the research community, and may use different Brefeldin_A tools and practices (an inventory is available at www.treat-nmd.eu/registries/docs/rare_inventory.pdf). These experts were invited by ENMC and TREAT-NMD to participate in a workshop to encourage collaborative action towards gene-based patient registries for rare, inherited muscle disorders in Europe and worldwide. The workshop concluded that harmonizing practices, joining forces and merging experience on gene-based patient registries may facilitate research into rare inherited muscle disorders, support upcoming clinical trials, and deliver standards of care (3).